Nature Communications (Aug 2021)
Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis
- Rosa Andres-Ejarque,
- Hira Bahadur Ale,
- Katarzyna Grys,
- Isabella Tosi,
- Shane Solanky,
- Chrysanthi Ainali,
- Zeynep Catak,
- Hemawtee Sreeneebus,
- Jake Saklatvala,
- Nick Dand,
- Emanuele de Rinaldis,
- Anna Chapman,
- Frank O. Nestle,
- Michael R. Barnes,
- Richard B. Warren,
- Nick J. Reynolds,
- Christopher E. M. Griffiths,
- Jonathan N. Barker,
- Catherine H. Smith,
- Paola Di Meglio,
- the PSORT Consortium
Affiliations
- Rosa Andres-Ejarque
- St. Johns Institute of Dermatology, Kings College London
- Hira Bahadur Ale
- St. Johns Institute of Dermatology, Kings College London
- Katarzyna Grys
- St. Johns Institute of Dermatology, Kings College London
- Isabella Tosi
- St. Johns Institute of Dermatology, Kings College London
- Shane Solanky
- St. Johns Institute of Dermatology, Kings College London
- Chrysanthi Ainali
- St. Johns Institute of Dermatology, Kings College London
- Zeynep Catak
- St. Johns Institute of Dermatology, Kings College London
- Hemawtee Sreeneebus
- St. Johns Institute of Dermatology, Kings College London
- Jake Saklatvala
- Department of Medical and Molecular Genetics, Kings College London
- Nick Dand
- Department of Medical and Molecular Genetics, Kings College London
- Emanuele de Rinaldis
- NIHR Biomedical Research Centre, Guys & St Thomas NHS Foundation Trust & King’s College London
- Anna Chapman
- Dermatology Department, Queen Elizabeth Hospital, Lewisham and Greenwich NHS Trust
- Frank O. Nestle
- St. Johns Institute of Dermatology, Kings College London
- Michael R. Barnes
- Centre for Translational Bioinformatics, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square
- Richard B. Warren
- Dermatology Centre, Salford Royal Hospital, The University of Manchester, Manchester Academic Health Science Centre
- Nick J. Reynolds
- Institute of Translational and Clinical Medicine, Newcastle University Medical School and Department of Dermatology, Royal Victoria Infirmary, Newcastle Hospitals NHS Foundation Trust
- Christopher E. M. Griffiths
- Dermatology Centre, Salford Royal Hospital, The University of Manchester, Manchester Academic Health Science Centre
- Jonathan N. Barker
- St. Johns Institute of Dermatology, Kings College London
- Catherine H. Smith
- St. Johns Institute of Dermatology, Kings College London
- Paola Di Meglio
- St. Johns Institute of Dermatology, Kings College London
- the PSORT Consortium
- DOI
- https://doi.org/10.1038/s41467-021-25066-9
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 16
Abstract
Biomarkers to indicate potential response to biologic therapeutics are needed for patients with psoriasis. Here the authors show that phosphorylation of NFκBp65 in cDC2 before therapy is an indication of non-response to the anti-TNF therapy adalimumab in patients with psoriasis.
